Return to Provider News

Streamlined Preauthorization for Medical Specialty Drugs for Commercial Fully Insured Members Effective January 1, 2023

Audience: Prescribing Providers

Based on feedback received from prescribing providers related to notification review/preauthorization requirements for medical specialty drugs, Excellus BlueCross BlueShield will update its requirements for commercial fully insured members effective January 1, 2023.  

To streamline the process and eliminate the need for providers to determine which patients have a benefit that requires notification review (post-service) versus preauthorization (pre-service) for medical specialty drugs, effective January 1, 2023, drugs included on our medical specialty drug preauthorization list will require preauthorization when administered to our commercial fully insured members.

Please check this list frequently for updates, as new drugs are added as they receive FDA approval and are available for use.

Thank you for sharing the feedback that led to this process update. We hope that you find it helpful in your day-to-day business with us.

Related News
Prior Authorization Updates for Elitek®, Abraxane® & Paclitaxel Protein- Bound Particles, Neulasta® and Udenyca® Effective March 1, 2023

Prior Authorization Update for Neulasta® and Udenyca® (pegfilgrastim) Effective March 1, 2023

Expansion of Child Health Plus Benefits Effective January 1, 2023

Medicare Advantage Prior Authorization for Select Oncology Medications

CareAdvance Provider Tool Expanding to Federal Employee Program





Utilization Management


GDPR Notification Content